A Phase 1a/1b clinical trial evaluating the safety, tolerability, and PK/PD of single and multiple-ascending dose of imdusiran in healthy subjects and patients with cHBV infection.

Preliminary data suggest that imdusiran is generally safe and well tolerated through 48 weeks of dosing and long-term suppression of HBsAg with imdusiran results in increased HBV-specific immune response. Patients who have discontinued all therapy are continuing to be followed.